CTRI/2017/08/009291已完成未知
A randomized, open-label, two-treatment, two-period, cross-over, multiple dose, steady state, multi-centre comparative bioequivalence study of Quetiapine Extended-Release Tablets, USP 400 mg manufactured by Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Rajoda, Ahmedabad, India for Amneal Pharmaceuticals, with SEROQUEL XR® (quetiapine fumarate extended release tablets) 400 mg manufactured by AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850 in patients suffering from schizophrenia under fasting conditions.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Either sex, aged 18 to 65 years (both inclusive) having clinical diagnosis of schizophrenia (DSM IV-TR)
- •2. Receiving a stable dose of Quetiapine Fumarate extended release tablets treatment for at least 1 month prior to randomization and is on Quetiapine Fumarate extended release tablets EQ 400 mg base once daily dosage at the time of screening.
- •3. Willing and able to comply with housing, restrictions and other protocol requirements as indicated by signed written informed consent witnessed by a legally acceptable representative.
- •4. Females of childbearing potential (who has not completed 1 year after menopause & have not gone through hysterectomy or bilateral tubal ligation) must have a negative pregnancy test (at screening, before randomization and before check-in to housing i.e., day 0) as well as must be non-lactating at screening and must agree to use an effective contraceptive method during study.
排除标准
- •1. History of allergic reactions to Quetiapine or other component of the extended release formulation.
- •2. Concurrent primary psychiatric or neurological diagnosis, including organic mental disorder, alcoholic and other toxic psychoses, severe tardive dyskinesia, or idiopathic Parkinsonâ??s disease.
- •3. History of suicidal tendencies (i.e., suicidal attempts) within the past 3 months prior to screening or immediate risk of harm to self or other at the time of screening, as judged by the investigator.
- •4. History of Neuroleptic Malignant Syndrome, cardiovascular disease [ischemic heart disease (including myocardial infarction), heart failure (including congestive heart failure or significant heart hypertrophy) or conduction abnormalities (including bradyarrythmia, congenital QT prolongation or family history of QT prolongation)], cerebrovascular disease, drug induced leucopenia/ neutropenia, seizures or with conditions that potentially lower the seizure threshold e.g. Alzheimerâ??s dementia
- •5. History of multiple syncopal episodes or presence of significant orthostatic hypotension at screening or before check-in to housing on day 0; Orthostatic hypotension will be considered when there is drop in systolic blood pressure of 30 mm Hg or more or diastolic blood pressure of 20 mm Hg or more on standing from supine measurements.
- •6. Current/ recent (within 3 months) history of uncontrolled epilepsy or risk for seizures
- •7. A medical or surgical condition that might interfere with theabsorption, metabolism or excretion of Quetiapine
- •8. Drug abuse or alcohol dependence in last 1 year period before enrolment (except dependence in full remission), as defined by DSM IV-TR criteria and as positive result in breath alcohol testing/ urine screen for drug of abuse (except for prescribed benzodiazepines).
- •9. Any of the following investigational abnormality in screening:
- •WBC count < 3000/mm3 (3.0x109
- •Absolute Neutrophil Count <1500/mm/l),3 (1.5x109)
- •Serum creatinine > 1.5 mg/dL /l),
- •QTc > 500 milliseconds (in ECG of screening or day 0)
- •SGOT/ SGPT >3 times Upper Limit of Normal range (ULN)
- •HbA1c > 9%
- •Reactive to anti-HIV, HBsAg, anti-HCV
- •10.Use of any of the following in the 14 days preceding enrolment including but not limited to:
- •Strong inhibitors of CYP3A4.
- •Strong inducers of CYP3A4.
- •Drugs associated with QT prolongation.
- •11. Participation in another clinical trial or use of other investigational product/ device within 4 weeks prior enrollment into this study.
- •12. Blood donation/blood loss exceeding 200 ml within 90 days prior to enrollment in the study.
- •13.Any condition/Abnormal baseline findings that in the investigatorsâ?? judgment might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study i.e., low expectation of compliance to dosing or expected changes in concomitant medication that may interfere in study.
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapsesMedDRA version: 12.0Level: PTClassification code 10028245Term: <Manually entered code. Term in E.1.1>Multiple sclerosisEUCTR2004-000555-42-DKSanofi-aventis US, Inc1,080
进行中（未招募）
1 期
To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's diseaseEUCTR2016-002976-28-ITOVARTIS PHARMA AG1,144
进行中（未招募）
1 期
Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CDZ173Primary Sjögren's syndromeMedDRA version: 19.0Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-004616-12-DEovartis Pharma Services AG30
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney diseaseType II Diabetes Mellitus and Diabetic Kidney DiseaseMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-000950-39-ITBAYER AG12,800
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-weektreatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of surinabant: 2.5, 5 and 10mg/day as an aid to smoking cessation in cigarette smokers - SURSMOKEAid to smoking cessation in cigarette smokersMedDRA version: 8.1Level: LLTClassification code 10057852Term: Nicotine dependenceEUCTR2006-005334-21-DEsanofi-aventis recherche et developpement805